ArticleJCEM case reports2026
Normalization of Potassium Despite 11-Deoxycorticosterone Rise During Etomidate Therapy in Adrenocortical Carcinoma.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is a rare malignancy often associated with disorganized steroid synthesis, leading to variable clinical phenotypes. Etomidate, an imidazole derivative, is a potent inhibitor of adrenal cytochrome P450-dependent enzymes, particularly 11β-hydroxylase (CYP11B1). Subhypnotic doses of etomidate are effective in reducing serum cortisol in patients with severe Cushing syndrome, a common manifestation in ACC. However, the effects of etomidate on other adrenal hormones in ACC remain poorly understood. In this report, we measured 13 steroid hormones before and after etomidate infusion using liquid chromatography-tandem mass spectrometry in a patient with ACC. Etomidate administration led to marked suppression of cortisol and aldosterone, while 11-deoxycorticosterone levels increased substantially. Interestingly, despite the elevated 11-deoxycorticosterone, serum potassium normalized, highlighting a complex interplay among mineralocorticoid precursors and active hormones in maintaining electrolyte balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.